The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).
 
Karen Anne Cadoo
Research Funding - AstraZeneca (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Michael L. Meyers
Employment - Syndax
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
 
Robert Allen Burger
Honoraria - Expertix
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Genentech/Roche; Gradalis; Janssen Research & Development; Merck; Morphotek; Tesaro; VBL Therapeutics
 
Deborah Kay Armstrong
Consulting or Advisory Role - CUE Biopharma
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
 
Richard T. Penson
Honoraria - Abbvie; Amgen; AstraZeneca; Baxalta; Clovis Oncology; Eisai; Genentech; Merck; Mersana; Sutter Medical Group; Tesaro; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Merck; Mersana; Sutter Medical Group; Tesaro; Vascular Biogenics
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst)
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics
Other Relationship - Abbvie
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; WCCT Global
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma; TRACON Pharma
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); BiolineRx (Inst); Calithera Biosciences (Inst); CanBas (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Hengrui Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); SynDevRx (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Gini F. Fleming
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Corcept Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
John William Moroney
No Relationships to Disclose
 
Erika Paige Hamilton
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Flatiron Health; Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ArQule (Inst); AstraZeneca (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Kadmon (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); Mallinckrodt (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Oncothyreon (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Verastem (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Linda R. Duska
Consulting or Advisory Role - Advance Medical; British Journal of Obstetrics and Gynecology; ClearView Healthcare Partners; Merck; Parexel; UpToDate
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
Other Relationship - Genentech; MedImmune; Merck
 
Robert Michael Wenham
Stock and Other Ownership Interests - Ovation Diagnostics
Honoraria - Tesaro
Consulting or Advisory Role - Clovis Oncology; Genentech; Merck; Mersana; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro
Research Funding - Merck (Inst); Prescient Therapeutics (Inst)
Travel, Accommodations, Expenses - TapImmune Inc.
 
Serap Sankoh
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Susan Brouwer
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Peter Ordentlich
Employment - Syndax
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
 
Carol Aghajanian
Consulting or Advisory Role - Clovis Oncology; Clovis Oncology; Clovis Oncology; Immunogen; Mateon Therapeutics; Mateon Therapeutics; Tesaro; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Fujifilm; Geneos; Immunogen; Merck; Mersana; Myriad Genetics
Research Funding - Merck; Novartis; Syndax; Tesaro